- Home
- COCH vs KRON Comparison
COCH vs KRON Comparison
Compare COCH & KRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COCH
- KRON
- Stock Information
- Founded
- COCH 1995
- KRON 2017
- Country
- COCH United States
- KRON United States
- Employees
- COCH N/A
- KRON N/A
- Industry
- COCH Blank Checks
- KRON Medicinal Chemicals and Botanical Products
- Sector
- COCH Finance
- KRON Health Care
- Exchange
- COCH Nasdaq
- KRON Nasdaq
- Market Cap
- COCH 64.4M
- KRON 60.3M
- IPO Year
- COCH N/A
- KRON 2020
- Fundamental
- Price
- COCH $1.84
- KRON $0.95
- Analyst Decision
- COCH Strong Buy
- KRON Buy
- Analyst Count
- COCH 4
- KRON 3
- Target Price
- COCH $8.00
- KRON $1.63
- AVG Volume (30 Days)
- COCH 42.8K
- KRON 376.8K
- Earning Date
- COCH 11-14-2024
- KRON 11-13-2024
- Dividend Yield
- COCH N/A
- KRON N/A
- EPS Growth
- COCH N/A
- KRON N/A
- EPS
- COCH N/A
- KRON N/A
- Revenue
- COCH $278,000.00
- KRON $9,864,000.00
- Revenue This Year
- COCH N/A
- KRON $62.21
- Revenue Next Year
- COCH $17.09
- KRON N/A
- P/E Ratio
- COCH N/A
- KRON N/A
- Revenue Growth
- COCH 15.35
- KRON 146.48
- 52 Week Low
- COCH $1.08
- KRON $0.69
- 52 Week High
- COCH $11.46
- KRON $1.60
- Technical
- Relative Strength Index (RSI)
- COCH 38.78
- KRON 48.89
- Support Level
- COCH $1.64
- KRON $0.92
- Resistance Level
- COCH $2.06
- KRON $1.03
- Average True Range (ATR)
- COCH 0.20
- KRON 0.06
- MACD
- COCH -0.02
- KRON -0.00
- Stochastic Oscillator
- COCH 38.24
- KRON 28.93
About COCH Envoy Medical Inc.
Envoy Medical Inc is a hearing health company focused on providing innovative medical technologies. It is dedicated to pushing hearing technology beyond the status quo to provide patients with improved access, usability, independence and quality of life.
About KRON Kronos Bio Inc.
Kronos Bio Inc is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine plan by targeting dysregulated transcription. The company operates in one business segment, the development of biopharmaceutical products.